First-generation (Crizotinib) and second-generation (Ceritinib, Alectinib, Brigatinib) TKIs are approved as first-line treatments for advanced ALK-positive NSCLC patients due to their proven survival benefits over chemotherapy. This evidence concerns the gene ALK and non-small cell lung carcinoma.